| http://ipc.inpi.gov.br/ipcpub |
Hanseníase; Hanseniasis
|
IPC |
A61K 39/008 |
Drug compositions containing antigens or antibodies (materials for immunoassay G01N 33/53) [2006.01] Leishmania antigens [2006.01] |
Discarded |
| A61K 31/045 |
Drug compositions containing organic active ingredients [2006.01] Hydroxy compounds, e.g., alcohols; salts thereof, e.g., alcoholates (hydroperoxides A61K 31/327) [2006.01] |
| A61K 31/4172 |
Drug compositions containing organic active ingredients [2006.01] imidazole-alkanocarboxylic acids, e.g., histidine [2006.01] |
| A61K 31/60 |
Drug compositions containing organic active ingredients [2006.01] Salicylic acid; derivate thereof [2006.01] |
| A61K 9/51 |
Drug compositions characterized by special physical forms [2006.01] Nanocapsules [2006.01] |
| Leprosy |
A61K 36/185 |
Drug compositions containing undetermined constitutional material derived from algae, lichens, fungi or plants, or derived thereof, e.g., traditional drugs based on herbal [2006.01] Magnoliopsida (dicotyledonous) [2006.01] |
| A61K 131/00 |
Indexing scheme associated with the A61K 36/00 group, relating to parts of plants with medicinal activity. [2006.01] containing or obtained from seeds, nuts, fruits or grains [2006.01] |
| A61K 31/00 |
Drug compositions containing organic active ingredients [2006.01] |
| A61K 31/045 |
Drug compositions containing organic active ingredients [2006.01] Hydroxy compounds, e.g., alcohols; salts thereof, e.g., alcoholates (hydroperoxides A61K 31/327) [2006.01] |
| A61K 31/07 |
Drug compositions containing organic active ingredients [2006.01] Retinol compounds, e.g., vitamin A (retinoic acid A61K 31/203) [2006.01] |
| https://www.wipo.int/classifications/ipc/ipcpub |
Leprosy
|
A61P 31/08 |
Anti-infectives, i.e. antibiotics, antiseptics, chemotherapeutics [2006.01] forleprosy[2006.01] |
Adopted |
| https://worldwide.espacenet.com/classification ?locale=en_EP |
Leprosy
|
CPC |
A61K31/00 |
Medicinal preparations containing organic active ingredients |
Discarded |
| C07D417/00 |
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 |
| A61K9/00 |
Medicinal preparations characterized by special physical form (nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations A61K49/18; preparations containing radioactive substances A61K51/12) |
| C07D487/00 |
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 |
| C07D519/00 |
Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 |
| C07D471/00 |
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 |
| C12Q1/00 |
Measuring or testing processes involving enzymes, nucleic acids or microorganisms (measuring or testing apparatus with condition measuring or sensing means, e.g. colony counters, C12M1/34); Compositions therefor; Processes of preparing such compositions |
| C07D279/00 |
Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms |
| Y02A50/00 |
in human health protection |
| C07D413/00 |
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms |
